Metabolic Asymmetry Relates to Clinical Characteristics and Brain Network Abnormalities in Alzheimer's Disease

J Alzheimers Dis. 2023;93(4):1395-1406. doi: 10.3233/JAD-221258.

Abstract

Background: Metabolic asymmetry has been observed in Alzheimer's disease (AD), but different studies have inconsistent viewpoints.

Objective: To analyze the asymmetry of cerebral glucose metabolism in AD and investigate its clinical significance and potential metabolic network abnormalities.

Methods: Standardized uptake value ratios (SUVRs) were obtained from 18F-FDG positron emission tomography (PET) images of all participants, and the asymmetry indices (AIs) were calculated according to the SUVRs. AD group was divided into left/right-dominant or bilateral symmetric hypometabolism (AD-L/AD-R or AD-BI) when more than half of the AIs of the 20 regions of interest (ROIs) were < -2SD, >2SD, or between±1SD. Differences in clinical features among the three AD groups were compared, and the abnormal network characteristics underlying metabolic asymmetry were explored.

Results: In AD group, the proportions of AD-L, AD-R, and AD-BI were 28.4%, 17.9%, and 18.5%, respectively. AD-L/AD-R groups had younger age of onset and faster rate of cognitive decline than AD-BI group (p < 0.05). The absolute values of AIs in half of the 20 ROIs became higher at follow-up than at baseline (p < 0.05). Compared with those in AD-BI group, metabolic connection strength of network, global efficiency, cluster coefficient, degree centrality and local efficiency were lower, but shortest path length was longer in AD-L and AD-R groups (p < 0.05).

Conclusion: Asymmetric and symmetric hypometabolism may represent different clinical subtypes of AD, which may provide a clue for future studies on the heterogeneity of AD and help to optimize the design of clinical trials.

Keywords: Alzheimer’s disease; Mini-Mental State Examination; cerebral glucose hypometabolism; graph theory; metabolic asymmetry; metabolic connectivity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease* / diagnostic imaging
  • Alzheimer Disease* / metabolism
  • Brain / diagnostic imaging
  • Brain / metabolism
  • Cognitive Dysfunction* / metabolism
  • Fluorodeoxyglucose F18 / metabolism
  • Humans
  • Metabolic Networks and Pathways
  • Positron-Emission Tomography / methods

Substances

  • Fluorodeoxyglucose F18